{"id":390468,"date":"2019-02-28T00:00:00","date_gmt":"2019-02-28T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0059-2019-biopharma-asthma-treatment-algorithms-claims-data-analysis-adult-asthma-us-2019\/"},"modified":"2026-05-04T11:38:38","modified_gmt":"2026-05-04T11:38:38","slug":"algoim0059-2019-biopharma-asthma-treatment-algorithms-claims-data-analysis-adult-asthma-us-2019","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0059-2019-biopharma-asthma-treatment-algorithms-claims-data-analysis-adult-asthma-us-2019\/","title":{"rendered":"Asthma | Treatment Algorithms: Claims Data Analysis | Adult Asthma | US | 2019"},"content":{"rendered":"

Pharmacotherapy<\/gwmw> for adult asthma has two main goals: address underlying airway inflammation and promote bronchodilation<\/gwmw>. Two types of therapy are used to achieve these goals\u2014maintenance therapy (e.g., a LABA\/ICS, such as GSK\u2019s Advair or AstraZeneca\u2019s Symbicort) and rescue therapy<\/gwmw> (e.g., a SABA, such as albuterol<\/gwmw>)<\/gwmw>\u2014and most adult asthma patients receive more than one drug to treat their condition. Although multiple well-established agents are available for both maintenance and rescue treatment, in the past few years, the adult asthma treatment landscape has witnessed the approval of the first branded-generic LABA\/ICS FDC (i.e., Teva\u2019s AirDuo<\/gwmw> and its generic), the first LAMA (i.e., Boehringer-Ingelheim\u2019s Spiriva), and several novel<\/gwmw> biologics<\/gwmw> (e.g., GSK\u2019s Nucala, Teva\u2019s Cinqair). The availability of these agents has expanded physicians\u2019 treatment arsenal and fueled increasing competition in the asthma therapy market. QUESTIONS ANSWERED What patient shares do key therapies and brands garner by line of therapy in newly diagnosed adult asthma patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed adult asthma patients? How have newer adult asthma therapies, such as Spiriva, Nucala, and Cinqair, been integrated into the treatment algorithm, and what are their sources of business? What percentage of adult asthma patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis? What percentage of adult asthma patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations? What are the product-level compliance and persistency rates among drug-treated patients? Geographies United States. Real-World Data Longitudinal patient-level claims data analysis. Key Drugs Covered Advair, Symbicort, Dulera, Breo, Spiriva, Xolair, Nucala, Cinqair, Qvar, ProAir, montelukast sodium. Key Analysis Provided Brand\/therapy usage across a longitudinal patient sample. Newly diagnosed patient analysis. Treatment initiation and progression. Line of therapy analysis. Combination therapy analysis. Source of business for recently treated patients. Persistency and compliance analysis. Product-level patient flowcharts. PRODUCT DESCRIPTION Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.<\/p>\n","protected":false},"template":"","class_list":["post-390468","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-asthma","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-931"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390468","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390468\/revisions"}],"predecessor-version":[{"id":576655,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390468\/revisions\/576655"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390468"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}